Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A study presented to the National Cancer Research (NCRI) Cancer Conference in Liverpool found that it could extend life by more than three months, in cases where disease had returned after treatment.
The cancer has one of the worst survival rates, because it is often symptomless until it is too late.
Each year around 7,000 women are diagnosed with the disease, which has a survival rate of 43 per cent.
The Cancer Research UK-funded trial found that patients given the new drug, cediranib, as well as conventional chemotherapy, survived for an extra three months, meaning they lived on average for just over 20 months after treatment started, instead of 17 and a half months.
Scientists said the drug is the first which has shown any delay in tumour progression in the fight against the disease.
http://www.telegraph.co.uk/health/h...offers-hope-to-women-with-ovarian-cancer.html
The cancer has one of the worst survival rates, because it is often symptomless until it is too late.
Each year around 7,000 women are diagnosed with the disease, which has a survival rate of 43 per cent.
The Cancer Research UK-funded trial found that patients given the new drug, cediranib, as well as conventional chemotherapy, survived for an extra three months, meaning they lived on average for just over 20 months after treatment started, instead of 17 and a half months.
Scientists said the drug is the first which has shown any delay in tumour progression in the fight against the disease.
http://www.telegraph.co.uk/health/h...offers-hope-to-women-with-ovarian-cancer.html